Iovance Biotherapeutics

Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » More on finance.yahoo.com

Iovance Biotherapeutics’ stock hit a 52-week high of $5.64 and is currently trading at $5.52, with a year-to-date return of about 101% and a 104% gain over the past six months. Market capitalization is $2.45 billion and annual revenue is $285.61 million (+34%). For Q1 2026 the company reported earnings per share of -$0.19 (expected -$0.14) and revenues of $71.4 million (expected $80.93 million). The Australian drug regulator granted conditional approval for the melanoma therapy Amtagvi, and Citizens reaffirmed a "market outperform" rating with a $5.00 price target, supported by ASCO presentations. » More on de.investing.com

Australia's Therapeutic Goods Administration granted conditional approval for Amtagvi, marking the drug's third marketing authorization and spurring a temporary stock rally that returned to pre-approval levels by June 10. Management now guides Q2 Amtagvi revenue of $79–81 million. Analyst sentiment is largely positive (about 80% bullish), though Chardan cut its price target from $16 to $14 citing revised launch timing. » More on finance.yahoo.com